Allostery and Biased Agonism at Class B G Protein-Coupled Receptors

Denise Wootten, Laurence J Miller, Cassandra Koole, Arthur Christopoulos, Patrick M. Sexton

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

Class B G protein-coupled receptors (GPCRs) respond to paracrine or endocrine peptide hormones involved in control of bone homeostasis, glucose regulation, satiety, and gastro-intestinal function, as well as pain transmission. These receptors are targets for existing drugs that treat osteoporosis, hypercalcaemia, Paget's disease, type II diabetes, and obesity and are being actively pursued as targets for numerous other diseases. Exploitation of class B receptors has been limited by difficulties with small molecule drug discovery and development and an under appreciation of factors governing optimal therapeutic efficacy. Recently, there has been increasing awareness of novel attributes of GPCR function that offer new opportunity for drug development. These include the presence of allosteric binding sites on the receptor that can be exploited as drug binding pockets and the ability of individual drugs to enrich subpopulations of receptor conformations to selectively control signaling, a phenomenon termed biased agonism. In this review, current knowledge of biased signaling and small molecule allostery within class B GPCRs is discussed, highlighting areas that have progressed significantly over the past decade, in addition to those that remain largely unexplored with respect to these phenomena.

Original languageEnglish (US)
Pages (from-to)111-138
Number of pages28
JournalChemical Reviews
Volume117
Issue number1
DOIs
StatePublished - Jan 11 2017

Fingerprint

G-Protein-Coupled Receptors
Pharmaceutical Preparations
Molecules
Peptide Hormones
Medical problems
Conformations
Bone
Binding Sites
Glucose

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Allostery and Biased Agonism at Class B G Protein-Coupled Receptors. / Wootten, Denise; Miller, Laurence J; Koole, Cassandra; Christopoulos, Arthur; Sexton, Patrick M.

In: Chemical Reviews, Vol. 117, No. 1, 11.01.2017, p. 111-138.

Research output: Contribution to journalReview article

Wootten, D, Miller, LJ, Koole, C, Christopoulos, A & Sexton, PM 2017, 'Allostery and Biased Agonism at Class B G Protein-Coupled Receptors', Chemical Reviews, vol. 117, no. 1, pp. 111-138. https://doi.org/10.1021/acs.chemrev.6b00049
Wootten, Denise ; Miller, Laurence J ; Koole, Cassandra ; Christopoulos, Arthur ; Sexton, Patrick M. / Allostery and Biased Agonism at Class B G Protein-Coupled Receptors. In: Chemical Reviews. 2017 ; Vol. 117, No. 1. pp. 111-138.
@article{5bf55b3477804a4688a205c742be09fe,
title = "Allostery and Biased Agonism at Class B G Protein-Coupled Receptors",
abstract = "Class B G protein-coupled receptors (GPCRs) respond to paracrine or endocrine peptide hormones involved in control of bone homeostasis, glucose regulation, satiety, and gastro-intestinal function, as well as pain transmission. These receptors are targets for existing drugs that treat osteoporosis, hypercalcaemia, Paget's disease, type II diabetes, and obesity and are being actively pursued as targets for numerous other diseases. Exploitation of class B receptors has been limited by difficulties with small molecule drug discovery and development and an under appreciation of factors governing optimal therapeutic efficacy. Recently, there has been increasing awareness of novel attributes of GPCR function that offer new opportunity for drug development. These include the presence of allosteric binding sites on the receptor that can be exploited as drug binding pockets and the ability of individual drugs to enrich subpopulations of receptor conformations to selectively control signaling, a phenomenon termed biased agonism. In this review, current knowledge of biased signaling and small molecule allostery within class B GPCRs is discussed, highlighting areas that have progressed significantly over the past decade, in addition to those that remain largely unexplored with respect to these phenomena.",
author = "Denise Wootten and Miller, {Laurence J} and Cassandra Koole and Arthur Christopoulos and Sexton, {Patrick M.}",
year = "2017",
month = "1",
day = "11",
doi = "10.1021/acs.chemrev.6b00049",
language = "English (US)",
volume = "117",
pages = "111--138",
journal = "Chemical Reviews",
issn = "0009-2665",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Allostery and Biased Agonism at Class B G Protein-Coupled Receptors

AU - Wootten, Denise

AU - Miller, Laurence J

AU - Koole, Cassandra

AU - Christopoulos, Arthur

AU - Sexton, Patrick M.

PY - 2017/1/11

Y1 - 2017/1/11

N2 - Class B G protein-coupled receptors (GPCRs) respond to paracrine or endocrine peptide hormones involved in control of bone homeostasis, glucose regulation, satiety, and gastro-intestinal function, as well as pain transmission. These receptors are targets for existing drugs that treat osteoporosis, hypercalcaemia, Paget's disease, type II diabetes, and obesity and are being actively pursued as targets for numerous other diseases. Exploitation of class B receptors has been limited by difficulties with small molecule drug discovery and development and an under appreciation of factors governing optimal therapeutic efficacy. Recently, there has been increasing awareness of novel attributes of GPCR function that offer new opportunity for drug development. These include the presence of allosteric binding sites on the receptor that can be exploited as drug binding pockets and the ability of individual drugs to enrich subpopulations of receptor conformations to selectively control signaling, a phenomenon termed biased agonism. In this review, current knowledge of biased signaling and small molecule allostery within class B GPCRs is discussed, highlighting areas that have progressed significantly over the past decade, in addition to those that remain largely unexplored with respect to these phenomena.

AB - Class B G protein-coupled receptors (GPCRs) respond to paracrine or endocrine peptide hormones involved in control of bone homeostasis, glucose regulation, satiety, and gastro-intestinal function, as well as pain transmission. These receptors are targets for existing drugs that treat osteoporosis, hypercalcaemia, Paget's disease, type II diabetes, and obesity and are being actively pursued as targets for numerous other diseases. Exploitation of class B receptors has been limited by difficulties with small molecule drug discovery and development and an under appreciation of factors governing optimal therapeutic efficacy. Recently, there has been increasing awareness of novel attributes of GPCR function that offer new opportunity for drug development. These include the presence of allosteric binding sites on the receptor that can be exploited as drug binding pockets and the ability of individual drugs to enrich subpopulations of receptor conformations to selectively control signaling, a phenomenon termed biased agonism. In this review, current knowledge of biased signaling and small molecule allostery within class B GPCRs is discussed, highlighting areas that have progressed significantly over the past decade, in addition to those that remain largely unexplored with respect to these phenomena.

UR - http://www.scopus.com/inward/record.url?scp=85018235637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018235637&partnerID=8YFLogxK

U2 - 10.1021/acs.chemrev.6b00049

DO - 10.1021/acs.chemrev.6b00049

M3 - Review article

C2 - 27040440

AN - SCOPUS:85018235637

VL - 117

SP - 111

EP - 138

JO - Chemical Reviews

JF - Chemical Reviews

SN - 0009-2665

IS - 1

ER -